<DOC>
	<DOC>NCT00965432</DOC>
	<brief_summary>The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension</brief_summary>
	<brief_title>A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107</brief_title>
	<detailed_description />
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Normal, healthy males 1850 years old, inclusive. Able to comprehend and willing to sign an Informed Consent Form (ICF). Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>